Clinical Trial Update: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular lymphoma and marginal zone lymphoma; recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: Brown University | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING